본문 바로가기
KERD
논문KCI 등재

이상지질혈증에 대한 택사탕(澤瀉湯)의 효과 : 체계적 문헌 고찰 및 메타 분석

The Effect of Taeksa-tang for Dyslipidemia: A Systematic Review and Meta-Analysis

허태영|김경민|이영서
대한한방내과학회 (The Society Of Korean Oriental Internal Medicine)|2023.06|대한한방내과학회지 (The Journal of Korean Oriental Internal Medicine)|제44권 제3호|pp. 485-505

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

meta-analysissystematic reviewhyperlipidemiadyslipidemiaTaeksa-tang
주제분류한의학

초록

Objective: The purpose of this study is to assess the effectiveness and safety of using Taeksa-tang for dyslipidemia through a systematic review and meta-analysis of randomized controlled trials (RCTs). Methods: The search was conducted using keywords such as “dyslipidemia”, “hyperlipidemia”, “taeksa tang”, “zexie tang”, and “takusha to” in 12 databases (Pubmed, Cochrane, Embase, ScienceDirect, CNKI, Wanfang, CiNii, RISS, KISS, ScienceON, OASIS, and DBpia) on April 13, 2023. There were no limits on the publication period and language. Cochrane’s risk of bias (RoB) was used to evaluate the quality of the studies. A meta-analysis was conducted according to the outcome measurements such as total effective rate (TER), total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and adverse effects, using the Review Manager web. Results: A total of 9 RCTs were selected. In evaluating the RoB, 2 studies mentioning the random sequence generation, 1 study conducting double blindness, and 8 studies without missing values were evaluated as low risk, while 1 study without mentioning the random sequence generation was evaluated as high risk. All other parts were evaluated as unclear risk. The treatment group (Taeksa-tang or Taeksa-tang-gagam) showed more statistically significant effects compared to the control group (Western medicine or Chinese patent medicine) in TER (RR : 1.24, 95% CI 1.15 to 1.34, P<0.00001), TC (MD : -1.12, 95% CI -1.68 to -0.56, P<0.0001), TG (MD : -1.08, 95% CI -1.65 to -0.51, P=0.0002), HDL-C (MD : 0.63, 95% CI 0.34 to 0.93, P<0.0001), LDL-C (MD : -0.81, 95% CI -1.10 to -0.53, P<0.00001). In addition, the treatment group showed lower adverse effects compared to the control group (RR : 0.30, 95% CI 0.12 to 0.74, P=0.008). Conclusion: This study suggests that Taeksa-tang is effective and safe to use for treating dyslipidemia. However, due to the low quality of the included studies, more clinical studies need to be conducted in the future to increase the possibility of clinical use.

Abstract

Objective: The purpose of this study is to assess the effectiveness and safety of using Taeksa-tang for dyslipidemia through a systematic review and meta-analysis of randomized controlled trials (RCTs). Methods: The search was conducted using keywords such as “dyslipidemia”, “hyperlipidemia”, “taeksa tang”, “zexie tang”, and “takusha to” in 12 databases (Pubmed, Cochrane, Embase, ScienceDirect, CNKI, Wanfang, CiNii, RISS, KISS, ScienceON, OASIS, and DBpia) on April 13, 2023. There were no limits on the publication period and language. Cochrane’s risk of bias (RoB) was used to evaluate the quality of the studies. A meta-analysis was conducted according to the outcome measurements such as total effective rate (TER), total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and adverse effects, using the Review Manager web. Results: A total of 9 RCTs were selected. In evaluating the RoB, 2 studies mentioning the random sequence generation, 1 study conducting double blindness, and 8 studies without missing values were evaluated as low risk, while 1 study without mentioning the random sequence generation was evaluated as high risk. All other parts were evaluated as unclear risk. The treatment group (Taeksa-tang or Taeksa-tang-gagam) showed more statistically significant effects compared to the control group (Western medicine or Chinese patent medicine) in TER (RR : 1.24, 95% CI 1.15 to 1.34, P<0.00001), TC (MD : -1.12, 95% CI -1.68 to -0.56, P<0.0001), TG (MD : -1.08, 95% CI -1.65 to -0.51, P=0.0002), HDL-C (MD : 0.63, 95% CI 0.34 to 0.93, P<0.0001), LDL-C (MD : -0.81, 95% CI -1.10 to -0.53, P<0.00001). In addition, the treatment group showed lower adverse effects compared to the control group (RR : 0.30, 95% CI 0.12 to 0.74, P=0.008). Conclusion: This study suggests that Taeksa-tang is effective and safe to use for treating dyslipidemia. However, due to the low quality of the included studies, more clinical studies need to be conducted in the future to increase the possibility of clinical use.

참고문헌 (37)

  1. "Cardiovascular diseases(CVDs)"[URL]
  2. 노지원, "스타틴으로 조절되지 않는 이상지질혈증 환자에게 대시호탕 복용이 미치는 영향", 대한한방내과학회지, 40(6), pp.1026~1034 (2019), 대한한방내과학회[DOI]
  3. The Korean Society of Lipid and Atherosclerosis (KSoLA) Committee of Clinical Practice Guideline, "Korean Guidelines for the Management of Dyslipidemia(the 5th edition)", The Korean Society of Lipid and Atherosclerosis, 19~ (2022)
  4. 유주영, "茵蔯, 鬱金, 枳實 추출물(ACA)이 HepG2 세포에서 나타나는 이상지질혈증 관련 인자 발현 및 항산화에 미치는 영향", 대한한방내과학회지, 38(3), pp.367~375 (2017), 대한한방내과학회
  5. Kim KS, "A Study on the Inhibitory Effects of Scutellariae Radix on Fat Accumulation", Korean Journal of Oriental Medicine, 9(2), pp.45~54 (2003)
  6. 안가영, "고지방 식이로 유발된 고지혈증 동물 모델에서 枸杞子加味方의 효과 연구", 대한한방내과학회지, 35(4), pp.505~518 (2014), 대한한방내과학회
  7. Bang HJ, "A Study on The Oriental-medical Understanding of Hyperlipidemia", The Journal of east-west medicines, 20(1), pp.25~36 (1995)
  8. 張仲景, "『金匱要略心典』 譯解", pp.214~216 (2008), Jipmoondang
  9. Lee KJ, "A case of dizziness patient suggested Benign Positional Vertigo treated by Zexictang", J Int Korean Med, 20(2), pp.705~710 (1999)
  10. Na HY, "A Case Report of Vertigo Patient with Vestibulopathy Improved with Zexie-tang", J Int Korean Med, (fal), pp.123~128 (2015)
  11. 이윤진, "택사탕의 항산화와 혈중지질에 대한 효과", 한방재활의학과학회지, 31(2), pp.1~14 (2021), 한방재활의학과학회
  12. Nam SK, "Studies on the Efficacy of Combined Preparation of Crude Drugs(XXXI)-The Effect of Taeksa-tang on Diuresis, Serum Lipid, Isolated Ileum, Heart, Blood Vessel, Blood Pressure and Respiration", Korean Journal of Pharmacognosy, 17(4), pp.263~271 (1986)
  13. 홍영기, "본초학적 접근을 통해 본 고지혈증의 최근 연구동향", 동의생리병리학회지, 24(1), pp.9~14 (2010), 한의병리학회
  14. NECA’s Guidance for Undertaking Systematic Reviews and Meta-analyses for Intervention, "Kim SY", National Evidence-based Health care Collaborating Agency, 1~287 (2011)
  15. 이준영, "메타분석", Endocrinology and Metabolism, 23(6), pp.361~378 (2008), 대한내분비학회
  16. 顾国龙, "泽泻汤治疗高血压病合并高脂血症", 湖北中医杂志, 25(4), pp.9~10 (2003)
  17. 展照双, "茯苓泽泻汤加味治疗高脂蛋白血症49例", 北京中医, 23(1), pp.24~26 (2004)
  18. 崔德成, "自拟泽泻柴胡汤治疗高脂血症的临床观察", 北京中医, 23(3), pp.152~153 (2004)
  19. 赵坤元, "“首乌泽泻汤” 治疗高脂血症60例临床观察", 江苏中医药, 27(5), pp.32~33 (2006)
  20. 秦泗关, "大黄茯苓泽泻汤治疗2型糖尿病合并高脂血症临床观察", CJCM, 4(18), pp.80~81 (2012)
  21. 高源, "泽泻汤在高脂血症治疗中的应用效果观察", 世界最新医学信息文摘, 16(61), pp.239~241 (2016)
  22. 何杰先, "泽泻汤治疗高脂血症的临床疗效观察", 双足与保健, 26(12), pp.178~179 (2017)
  23. 李爱珍, "泽泻汤治疗高脂血症的临床疗效", 临床合理用药杂志, 11(36), pp.114~115 (2018)
  24. 李白云, "大黃蟅虫丸合泽泻汤加减治疗高脂血症60例临床观察", 哈尔滨医药, 39(2), pp.187~188 (2019)
  25. Heber D, "Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement", Am J Clin Nutr, 69(2), pp.231~236 (1999)
  26. Liang L, "Xuezhikang improves the outcomes of cardiopulmonary resuscitation in rats by suppressing the inflammation response through TLR4", NF-κB pathway, 2019, pp.114, 108817~
  27. Xu G, "Comparing the effectiveness of Chinese patent medicines containing red yeast rice on hyperlipidaemia : A network meta-analysis of randomized controlled trials", Endocrinol Diabetes Metab, 5(1), pp.e00314~ (2022)
  28. Hao SY, "Simultaneous determination of lovastatin and lovastatin acid in fermentum Rubrum and Zhibituo tablets by QAMS", Chin J Exp Trad Med Formulae, 23, pp.74~78 (2017)
  29. Khorshidi M, "Effect of evening primrose oil supplementation on lipid profile : A systematic review and meta-analysis of randomized clinical trials", Phytother Res, 34(10), pp.2628~2638 (2020)
  30. Statistics Korea, "2021 Death statistics", Statistics Korea, 6~ (2021)
  31. Ahmed Arafa, "Modifiable Risk Factors for Cardiovascular Disease in Korea and Japan", Korean Circulation Journal, 51(8), pp.643~655 (2021), 대한심장학회[DOI]
  32. 2020 Chronic Disease Status and Issues - Chronic Disease Factbook, "Korea Disease Control and Prevenion Agency", Korea Disease Control and Prevenion Agency, 17~74 (2020)
  33. Maningat P, "How do we improve patient compliance and adherence to long-term statin therapy", Current Atherosclerosis Reports, 15(1), pp.291~ (2013)
  34. 이세라, "의약품부작용보고시스템 데이터베이스를 이용한 고강도 statin과 중·저강도 statin 관련 이상사례 비교 분석", 한국임상약학회지, 28(4), pp.293~299 (2018), 한국임상약학회[DOI]
  35. Yang YG, "The translation of Hwangjenaegyung", pp.296~297 (1991), Iljoongsa
  36. Heo J, "Donguibogam", pp.128~ (1975), Namsandang
  37. College of Oriental Medicine Herbology Compilation Committee, "Herbology", pp.348~349 (2010), Yeongrimsa

관련 논문AI추천

스타틴으로 조절되지 않는 이상지질혈증 환자에게 대시호탕 복용이 미치는 영향김동현, 노지원, 안세영, 안영민, 유정화, 이병철, 정수민대한한방내과학회 · 대한한방내과학회지2019 · 제40권 제6호본초학적 접근을 통해 본 고지혈증의 최근 연구동향김성수, 김진주, 신민규, 홍영기한의병리학회 · 동의생리병리학회지2010 · 제24권 제1호대사이상 지방간질환 한약치료의 임상적 효과와 연구동향 : 체계적 문헌 고찰 및 메타분석공건식, 김소림, 김진현, 박수나, 서민조, 선민지, 이지원, 최요섭대한한방내과학회 · 대한한방내과학회지2025 · 제46권 제4호비알콜성 지방간질환의 한방치료에 대한 체계적 문헌고찰김경순, 김승모, 이유리, 조나경, 최홍식대한한방내과학회 · 대한한방내과학회지2019 · 제40권 제1호고중성지방혈증에 대한 단기 한약 투약 경과 : 증례보고김보민, 조희근대한한방내과학회 · 대한한방내과학회지2019 · 제40권 제3호고혈압에 대한 한약 이수 처방 효과에 대한 체계적 문헌 고찰 및 메타분석강기완, 강자연, 김홍준, 장인수, 정민정대한한방내과학회 · 대한한방내과학회지2017 · 제38권 제6호

이 간행물의 다른 논문 (20건)

Yukgunja-tang for Irritable Bowel Syndrome: A Protocol for a Systematic Review and Meta-Analysis박재우, 고석재, 김민정, 박채현, 조민석, 이강욱pp. 285-293Ovalbumin으로 유발된 천식 동물모델에서 GGX의 효과김태현, 우성천, 김승형, 양원경, 이수원, 박양춘pp. 294-312심부전의 한약 임상연구에 활용된 한약재에 대한 기구축 DB(K-HERB NETWORK)를 활용한 네트워크 분석박수빈, 배기상, 김예지, 김철현, 윤인애, 추홍민, 임정태pp. 313-353제2형 당뇨병 환자에서 혈당강하제와 보중익기탕 병용 투여가 혈당 변화에 미치는 영향 및 안전성 연구송미령, 노지원, 안영민, 안세영, 이병철, 정우녕, 오승현pp. 354-365특발성 폐섬유증의 통합의료 협진 모델 개발을 위한 의료진 및 환자 대상 설문조사 연구최혜숙, 이범준, 신정원, 정희재, 진수현, 김관일, 양정민, 김수덕, 박지원pp. 366-386
원문 보기